ABSTRACT
INTRODUCTION
Primary biliary cirrhosis (PBC) is an autoimmune liver disease of unknown etiology and is characterized by chronic progressive cholestasis with destruction of the small intrahepatic bile ducts and associated most commonly with antimitochondrial antibodies. 1, 2, 3 The disease is uncommon, with a reported prevalence between 19 and 402 cases per million. The vast majority (90%) of patients affected are women, with the usual time of diagnosis between 30 and 60 years. The diagnosis of PBC is based on three criteria: elevation of liver enzymes (most commonly ALP and γ-GT), presence of detectable AMA in the serum, and liver histologic findings that are compatible with the presence of the disease. 4 PBC is most common in women and is often associated with other autoimmune disease such as autoimmune hemolityc anemia (AIHA), rheumatoid arthritis, thyroiditis, and systemic lupus eritomatosus. Autoimmune hemolytic anemia involves an autoimmune process and is caused by a hemolysis induced by the reaction of autoantibodies with red blood cells (RBCs) and it's characterized by a positive direct Coombs' test. It is idiopathic (primary) in approximately 50% cases or secondary to medication, hematological malignancies and autoimmune disorders. [5] [6] [7] [8] [9] AIHA is also a rare disease with incidences reported in the range of 1 per 75,000 to 2 per 100,000. Primary or idiopathic AIHA accounts for less than half of the cases and most patients will be found to have underlying associated conditions including tumors, autoimmune diseases, or an acquired immunodeficiency syndrome. The association between primary biliary cirrhosis (PBC) and autoimmune hemolytic anemia (AIHA) is uncommon. Despite the autoimmune basis of PBC, there have been few reports of PBC in association with AIHA. 10 The recommended treatment for PBC-related AIHA includes sufficient doses of corticosteroids to control the hemolysis at the acute phase, and immunosuppressant (for example CTX and CsA) or adequate dose of UDCA to maintain therapy. 11 We describe a case of AIHA in association with PBC, which responded to ursodeoxycholic acid (UDCA) used as sole treatment.
CASE ILLUSTRATION
We report a 20 years old woman with AIHA have been treated by corticosteroid since last year and she came to the outpatient department (OPD) with fatique and jaundice. From the physical examination, we found palor, hepatosplenomegaly, no lymphadenopathy. The result of laboratory were haemoglobin 8.7 mg/dL, white blood cell 8,700 mg/dL, coomb test +2, total bilirubin 33.2 mg/dL, direct bilirubin 29.3 mg/dL, γGT: 297 mg/dL and alkalyphospatase: 158 mg/dL. Cause of jaundice, we did the Abdominal CT Scan. After treatment with corticosteroid (prednison 1mg/kg/day) and ursodeoxicholic acid (UDCA) for several weeks, the clinical manifestation of PBC such as jaundice getting better (the laboratory result: total bilirubin 2.7 mg/dL, direct bilirubin 1.5 mg/dL, gamma GT 80mg/dL).
DISCUSSION
Primary biliary cirrhotic is a slowly progressive autoimmune disease. The diagnosis of PBC is based on three criteria: elevation of liver enzymes (most commonly ALP and γ-GT), presence of detectable AMA in the serum, and liver histologic findings that are compatible with the presence of the disease. 9 While AIHA is also an immune disease which is caused by antibodies directed against autologous red cells, the diagnosis is based on the presence of anemia, signs of hemolysis with reticulocytosis, increased lactate dehydrogenase, elevated indirect bilirubin, and a positive Coombs' test.
2 Not all patients with PBC received the diagnosis when it was at an early stage because of their asymptomatic status, and it is supposed that PBC occurred after AIHA development 
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Young Woman in these patients. 9 The occurrence suggests a possible relationship between the two diseases. PBC patients are likely to have some conditions which can induce generation of anti-erythrocyte antibodies. 8 Corticosteroid treatment is not only a preferred therapy for AIHA, but an adjuvant therapy that benefits PBC patients. 11 According to the criteria of secondary AIHA: (1) AIHA would occur on the basis of PBC; (2) Reversal of AIHA and liver function improvement of PBC happened simultaneously with the intake of immunosuppressive agents; (3) Both PBC and AIHA are known to be immune-mediated diseases. Thus, we could call them PBC-related AIHA. Serum bilirubin levels have long been known to be important in assessing the prognosis of PBC, but confounding hemolysis may lead to erroneous conclusions about the severity of PBC. 2 At the same time, compared with primary AIHA, this PBC-related AIHA is lifethreatening but can be controlled. If no attention is paid to this condition, primary PBC will be ignored, as 50-60% of PBC patients are asymptomatic at diagnosis. 12 Therefore patients with PBC whose serum bilirubin levels rise suddenly should undergo screening for associated hemolysis.
The recommended treatment for PBC-related AIHA includes sufficient doses of corticosteroids to control the hemolysis at the acute phase, and immunosuppressant (for example CTX and CsA) or adequate dose of UDCA to maintain therapy. To deal with the severe, life-threatening hemolysis, intravenous immunoglobulin and large dosage of corticosteroids impact therapy may be considered. Only UDCA therapy for PBC patients with mild AIHA had a successful report, so in mild cases this method could be considered with regular blood cell counts to monitor response. Although Kaibori et al provided a successful case that could confirm liver transplantation and splenectomy is a curative therapy to PBC-related AIHA. 5, 8 
